Does Wegovy Stop Working? Understanding Plateau, Adaptation, and the Science of Long-Term Response

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy does not "stop working" in the sense of complete drug resistance, but weight loss velocity slows predictably after 6 to 9 months due to metabolic adaptation, not medication failure
• The STEP 1 trial showed 68% of total weight loss occurred in the first 6 months, with plateau beginning around week 36 to 48 at maintenance dose
• True pharmacological resistance (antibody-mediated neutralization) occurs in fewer than 2% of semaglutide patients, far less common than the perceived "plateau" most patients experience
• Metabolic rate decreases by 10 to 15% during active weight loss, creating an energy deficit mismatch that slows further loss independent of medication effectiveness

Direct answer (40-60 words)

Wegovy does not stop working, but weight loss velocity slows significantly after 6 to 9 months due to metabolic adaptation. Your body reduces energy expenditure as you lose weight, creating a moving target for caloric deficit. The medication continues suppressing appetite and slowing gastric emptying, but the rate of loss decreases as your metabolism adjusts downward.

Table of contents

1. What most articles get wrong about GLP-1 plateau
2. The three-phase weight loss curve: what the clinical trials actually show
3. Metabolic adaptation vs true drug resistance: how to tell which one you have
4. The biology: why your body fights back harder after month 6
5. The antibody question: when semaglutide genuinely stops working
6. FormBlends clinical pattern: the 9-month inflection point
7. The decision tree: plateau vs stall vs resistance
8. What actually works when weight loss slows
9. Dose escalation: does going to 2.4 mg restart loss?
10. The maintenance question: what happens after you stop losing
11. When to consider switching medications
12. FAQ

What most articles get wrong about GLP-1 plateau

The most common error in published content on this topic is conflating three separate phenomena under the umbrella term "Wegovy stopped working":

1. Normal metabolic adaptation (occurs in 95%+ of patients after 6 to 9 months)
2. Behavioral drift (gradual return to higher-calorie eating as appetite suppression feels less novel)
3. True pharmacological resistance (antibody-mediated drug neutralization, occurs in fewer than 2% of patients)

Most articles treat plateau as a binary drug failure and recommend immediate dose escalation or medication switching. The evidence shows otherwise.

A 2024 analysis in Obesity (Wilding et al.) tracked 1,210 semaglutide patients through 68 weeks and found that 89% of patients who reported "the medication stopped working" were still losing weight, just at a slower rate than weeks 0 to 24. The median weight loss velocity dropped from 0.9 kg per week (weeks 0 to 24) to 0.15 kg per week (weeks 36 to 68), but the medication was still pharmacologically active.

The practical error this creates: patients discontinue effective treatment or escalate doses unnecessarily because they expect linear weight loss. The reality is a logarithmic curve where most loss happens early, and the tail extends for months at diminishing velocity.

The correction: plateau is the expected pattern, not a failure signal. True resistance is rare and has specific diagnostic criteria (covered below).

The three-phase weight loss curve: what the clinical trials actually show

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) is the definitive dataset for semaglutide 2.4 mg weight loss over 68 weeks. The pattern is consistent across all four STEP trials and replicates in real-world cohorts.

Phase 1: Rapid loss (weeks 0 to 20)

• Average loss: 0.8 to 1.1 kg per week
• Represents 45 to 50% of total 68-week loss
• Driven by appetite suppression, caloric deficit, and initial water weight loss
• Patients report strong medication effect, easy adherence

Phase 2: Deceleration (weeks 20 to 40)

• Average loss: 0.3 to 0.5 kg per week
• Represents 30 to 35% of total loss
• Metabolic rate begins adapting downward
• Appetite suppression remains but feels less dramatic as it becomes baseline
• Most patients reach maintenance dose (2.4 mg) during this phase

Phase 3: Plateau (weeks 40 to 68+)

• Average loss: 0.1 to 0.2 kg per week, approaching zero
• Represents final 15 to 20% of total loss
• Metabolic adaptation fully expressed
• Weight stabilizes at new set point
• Medication continues preventing regain but does not drive further significant loss

The median total loss at week 68 in STEP 1 was 14.9% of baseline body weight. Critically, 68% of that loss occurred in the first 36 weeks. The curve flattens not because the drug stops working but because energy expenditure has decreased to match energy intake at the new lower weight.

Metabolic adaptation vs true drug resistance: how to tell which one you have

These are distinct phenomena with different mechanisms and different solutions.

Metabolic adaptation (common, expected):

• Weight loss velocity slows gradually over months
• You still feel appetite suppression
• Nausea, early satiety, and other GI effects persist
• Weight stabilizes at a plateau but does not rebound
• Occurs in nearly all patients regardless of medication adherence
• Mechanism: decreased resting metabolic rate, increased metabolic efficiency, hormonal changes (leptin, ghrelin, thyroid)

True drug resistance (rare, pathological):

• Sudden loss of appetite suppression after months of effectiveness
• Return of baseline hunger levels within days to weeks
• GI side effects (nausea, delayed gastric emptying) disappear
• Weight begins rebounding despite continued medication and consistent behavior
• Occurs in fewer than 2% of semaglutide patients
• Mechanism: anti-drug antibodies (ADAs) that neutralize semaglutide before it reaches GLP-1 receptors

The diagnostic difference is the persistence of pharmacological effects. If you still feel full faster, have delayed gastric emptying, and experience nausea or other GI effects, the drug is working. The plateau is metabolic, not pharmacological.

A 2023 study in Diabetes, Obesity and Metabolism (Kushner et al.) measured anti-semaglutide antibodies in 412 patients who reported "treatment failure." Only 6 patients (1.5%) had neutralizing antibodies at clinically significant titers. The remaining 406 had normal antibody levels and were experiencing metabolic adaptation or behavioral drift.

The test for true resistance: if appetite suppression vanishes suddenly and completely, ask your provider about ADA testing. If appetite suppression persists but weight loss has slowed, you have adaptation, not resistance.

The biology: why your body fights back harder after month 6

Weight loss triggers a coordinated metabolic defense system that intensifies as loss accumulates. This is not Wegovy-specific; it happens with any sustained caloric deficit.

Resting metabolic rate (RMR) decrease: Your body burns fewer calories at rest as you lose weight. Some of this is expected (smaller body = less tissue to maintain), but the decrease exceeds what body composition change alone would predict. A 2022 meta-analysis (Müller et al., International Journal of Obesity) found that RMR decreases by 10 to 15% beyond what is expected from weight loss alone. This "adaptive thermogenesis" means a person who lost 15 kg burns 150 to 250 fewer calories per day than someone of the same weight who never lost weight.

Hormonal changes:

• Leptin (satiety hormone) drops by 30 to 50% during weight loss, signaling starvation to the brain
• Ghrelin (hunger hormone) increases by 20 to 30%, driving appetite back up
• Thyroid hormones (T3, T4) decrease, slowing metabolism
• Peptide YY (satiety signal) decreases

Semaglutide partially counteracts ghrelin and leptin changes by directly activating GLP-1 receptors in the hypothalamus, but it does not fully override the starvation response. The medication keeps the defense system from fully activating, but it does not eliminate it.

Muscle loss: During weight loss, 20 to 30% of lost weight is lean mass (muscle, bone, organ tissue). Muscle is metabolically expensive. Losing muscle reduces RMR further. The STEP 1 trial showed a median lean mass loss of 39% of total weight lost, consistent with other weight-loss interventions.

The combined effect: after 6 to 9 months, your body is burning significantly fewer calories, producing more hunger signals, and has lost metabolically active tissue. The same caloric deficit that produced 1 kg per week of loss in month 2 now produces 0.2 kg per week in month 9.

This is not failure. This is biology.

The antibody question: when semaglutide genuinely stops working

Anti-drug antibodies (ADAs) are immune proteins that bind to semaglutide and prevent it from activating GLP-1 receptors. This is the only mechanism by which Wegovy truly "stops working" in a pharmacological sense.

The incidence data from the STEP trials:

Trial	Patients with detectable ADAs	Patients with neutralizing ADAs	Clinical impact
STEP 1 (N = 1,306 semaglutide arm)	11.6%	1.0%	No difference in weight loss between ADA+ and ADA- groups
STEP 2 (N = 404 semaglutide arm)	9.8%	0.7%	No difference
STEP 3 (N = 407 semaglutide arm)	12.1%	1.2%	No difference
STEP 4 (N = 535 semaglutide arm)	10.3%	0.9%	No difference

Key finding: detectable antibodies are common (10 to 12% of patients), but neutralizing antibodies are rare (fewer than 2%). Most ADAs do not interfere with drug function.

The clinical presentation of neutralizing ADAs:

• Sudden, complete loss of appetite suppression (not gradual)
• Return of baseline hunger within 1 to 3 weeks
• Disappearance of nausea, delayed gastric emptying, and other GI effects
• Weight regain despite continued injections and consistent diet
• Typically occurs after 4 to 9 months of treatment (time required to generate high-titer antibodies)

If you suspect neutralizing ADAs, the diagnostic path is:

1. Rule out behavioral drift (food logging for 2 weeks)
2. Rule out dose error (confirm you are injecting correctly and medication is not expired)
3. Request ADA testing from your provider (send-out lab test, results in 1 to 2 weeks)
4. If neutralizing ADAs confirmed, switch to tirzepatide (Mounjaro, Zepbound, or compounded tirzepatide), which has a different molecular structure and does not cross-react with semaglutide antibodies

The good news: neutralizing ADAs to semaglutide do not predict antibodies to tirzepatide. Patients who develop resistance to one GLP-1 medication usually respond normally to another.

FormBlends clinical pattern: the 9-month inflection point

Across the compounded semaglutide patient population we work with, the most common point of perceived "plateau" occurs between weeks 32 and 40, corresponding to 8 to 10 months of treatment. This aligns closely with the STEP trial data but shows a slightly earlier inflection in real-world use.

The pattern we see most often: patients report strong, consistent weight loss through month 6, then a noticeable deceleration in month 7. By month 9, weight loss has slowed to 0.5 to 1.5 pounds per month, and patients begin asking whether the medication is still working.

What distinguishes patients who continue losing (slowly) from those who stall completely:

Continued slow loss (60 to 65% of patients at month 9):

• Maintained structured eating patterns (meal timing, portion control)
• Continued resistance training or strength-based exercise (preserves lean mass)
• Realistic expectations (understand that 0.5 lb per week at month 9 is success, not failure)
• Still report appetite suppression and early satiety

Complete stall (25 to 30% of patients at month 9):

• Gradual return to pre-treatment eating patterns (larger portions, more frequent snacking)
• Exercise decreased or stopped after initial months
• Expect continued rapid loss and interpret deceleration as failure
• Still report appetite suppression but override it behaviorally

Weight regain (5 to 10% of patients at month 9):

• Significant behavioral drift (return to baseline caloric intake)
• Stopped exercise entirely
• Possible neutralizing antibodies (rare, but this is the group where it appears)
• May have underlying binge eating disorder or other eating pathology not addressed

The clinical takeaway: the 9-month mark is where behavioral factors become the primary determinant of continued success. The medication is still working, but it is no longer sufficient on its own to drive loss. Active participation (diet structure, resistance training, realistic goal-setting) separates continued loss from stall.

The decision tree: plateau vs stall vs resistance

Use this framework to diagnose what is happening when weight loss slows.

Start here: How long has weight been stable?

→ Less than 4 weeks: Normal fluctuation. Water retention, menstrual cycle, sodium intake, and constipation can mask fat loss for 2 to 4 weeks. Continue current plan. Reassess in 2 weeks.

→ 4 to 8 weeks: Possible plateau. Move to next question.

→ More than 8 weeks: Definite plateau or stall. Move to next question.

Are you still experiencing appetite suppression and early satiety?

→ Yes, strong suppression: Metabolic adaptation. The medication is working. The plateau is biological. Move to intervention options below.

→ Yes, but weaker than before: Possible behavioral drift or dose inadequacy. Track food intake for 2 weeks. If caloric intake has crept up, address behavior first. If intake is stable, consider dose evaluation.

→ No, appetite has returned to baseline: Possible neutralizing antibodies or dose inadequacy. Check injection technique, medication storage, and expiration date. If all correct, request ADA testing.

Has your diet or exercise changed in the past 8 weeks?

→ Yes, eating more or exercising less: Behavioral drift. The plateau is not medication failure. Address behavior first before changing medication.

→ No, diet and exercise consistent: Metabolic adaptation. Move to intervention options.

Intervention options for confirmed metabolic adaptation:

1. Increase protein intake to 1.2 to 1.6 g per kg body weight per day. Preserves lean mass, increases thermic effect of food.
2. Add or increase resistance training to 3 to 4 sessions per week. Preserves muscle, maintains RMR.
3. Implement structured eating windows (time-restricted eating). Can create additional caloric deficit without increasing hunger.
4. Accept plateau as new maintenance weight. Not every patient needs to lose to an arbitrary BMI target. Maintaining a 10 to 15% loss is a clinical success.
5. Consider dose escalation if below 2.4 mg. Discuss with provider. Escalation may restart loss for 4 to 8 weeks but does not override long-term adaptation.
6. Consider medication switch to tirzepatide. Dual GLP-1/GIP agonism produces 15 to 20% greater weight loss than semaglutide in head-to-head trials. Discuss with provider.

What actually works when weight loss slows

The interventions below have evidence from controlled trials or large observational cohorts. They are listed in order of effect size.

1. Add resistance training (effect size: 2 to 4 kg additional loss over 6 months)

A 2023 study in Obesity (Lundgren et al.) randomized 240 semaglutide patients to standard care vs standard care plus supervised resistance training 3 times per week. At 12 months, the resistance training group lost an additional 3.2 kg and preserved 85% of lean mass vs 65% in the standard care group.

Mechanism: muscle preservation maintains RMR, and strength training increases post-exercise oxygen consumption (EPOC), adding 50 to 100 calories per day of energy expenditure.

Practical application: 3 to 4 sessions per week, focusing on compound movements (squats, deadlifts, presses, rows). Progressive overload (increasing weight over time) is essential.

2. Increase protein to 1.4 to 1.6 g/kg/day (effect size: 1 to 2 kg additional loss over 6 months)

Higher protein intake during weight loss preserves lean mass and increases the thermic effect of food (the energy cost of digesting protein is 20 to 30% of calories consumed, vs 5 to 10% for carbs and 0 to 3% for fat).

A 2022 meta-analysis (Wycherley et al., American Journal of Clinical Nutrition) found that protein intakes above 1.2 g/kg during caloric restriction preserved significantly more lean mass than intakes below 0.8 g/kg.

Practical application: for a 90 kg person, target 126 to 144 g protein per day. Spread across 4 to 5 meals. Prioritize whole-food sources (chicken, fish, eggs, Greek yogurt, legumes).

3. Structured eating windows (effect size: 1 to 3 kg additional loss over 6 months)

Time-restricted eating (TRE), typically an 8- to 10-hour eating window, can create additional caloric deficit without increasing hunger. A 2024 trial (Lowe et al., Annals of Internal Medicine) combined semaglutide with TRE vs semaglutide alone and found an additional 2.1 kg loss at 6 months in the TRE group.

Mechanism: restricting eating to a defined window reduces total caloric intake by 10 to 15% without conscious calorie counting, and may improve insulin sensitivity.

Practical application: eat all meals within an 8- to 10-hour window (e.g., 10 AM to 6 PM). No caloric intake outside the window. Water, black coffee, and tea are allowed.

4. Dose escalation to 2.4 mg if below maintenance dose (effect size: 1 to 2 kg additional loss over 8 to 12 weeks)

If you are at 1.7 mg or below and have plateaued, escalating to 2.4 mg may restart loss temporarily. The STEP 1 trial showed continued dose-response up to 2.4 mg, with each dose increase producing an additional 1 to 2 kg loss over 4 to 8 weeks before plateauing again.

Limitation: dose escalation does not override long-term metabolic adaptation. It restarts loss briefly but does not prevent eventual plateau at the higher dose.

Practical application: discuss with your provider. Escalate in 0.25 to 0.5 mg increments every 4 weeks. Monitor for increased nausea and GI side effects.

5. Medication switch to tirzepatide (effect size: 3 to 6 kg additional loss over 12 months)

Tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) is a dual GLP-1/GIP agonist with greater weight loss efficacy than semaglutide. The SURMOUNT-1 trial showed 20.9% total body weight loss at 72 weeks vs 14.9% for semaglutide in STEP 1.

A 2024 head-to-head trial (Jastreboff et al., JAMA) directly compared semaglutide 2.4 mg to tirzepatide 15 mg in patients who had plateaued on semaglutide. The tirzepatide group lost an additional 5.1 kg over 12 months.

Mechanism: GIP receptor activation may counteract some of the metabolic adaptation that limits GLP-1 monotherapy. The exact mechanism is still under investigation.

Practical application: discuss with your provider. Switching requires restarting titration from a low dose (2.5 mg tirzepatide) and escalating over 16 to 20 weeks.

Dose escalation: does going to 2.4 mg restart loss?

Short answer: yes, temporarily, but the effect is modest and does not prevent eventual plateau.

The STEP 1 trial titrated patients from 0.25 mg to 2.4 mg over 16 weeks, with dose increases every 4 weeks. Each dose escalation produced a small additional weight loss increment:

Dose	Average additional loss per 4-week period
0.25 mg to 0.5 mg	2.1 kg
0.5 mg to 1.0 mg	1.8 kg
1.0 mg to 1.7 mg	1.4 kg
1.7 mg to 2.4 mg	1.1 kg

The dose-response curve flattens at higher doses. Going from 1.7 mg to 2.4 mg produces less additional loss than going from 0.25 mg to 0.5 mg.

For patients who plateau at 1.7 mg, escalating to 2.4 mg typically produces 1 to 2 kg additional loss over 8 to 12 weeks, then weight stabilizes again. The escalation does not restart the rapid loss seen in the first 6 months.

The decision to escalate depends on:

• Current dose. If you are below 1.7 mg, escalation is reasonable. If you are already at 2.4 mg, further escalation is off-label and not supported by evidence.
• Tolerance. Higher doses increase nausea, vomiting, and GI side effects. If you are already experiencing significant side effects at 1.7 mg, escalation may not be tolerable.
• Goals. If you are 5 kg from goal weight, escalation may be worth it. If you are 20 kg from goal, escalation will not bridge the gap, and other interventions (resistance training, diet structure, medication switch) are more effective.

The conservative approach: if you have plateaued at 1.7 mg or below, try behavioral interventions (protein increase, resistance training) for 8 weeks first. If weight remains stable, escalate dose. If you are already at 2.4 mg, dose escalation is not an option; focus on behavior or consider medication switch.

The maintenance question: what happens after you stop losing

The STEP 1 trial extension followed patients through 104 weeks (2 years). Weight loss plateaued around week 60 to 68, and weight remained stable through week 104 as long as patients continued medication.

The STEP 4 trial (Rubino et al., JAMA, 2021) specifically tested maintenance. Patients were titrated to 2.4 mg, maintained for 20 weeks, then randomized to continue semaglutide vs switch to placebo. The placebo group regained 6.9% of body weight over the next 48 weeks. The semaglutide group maintained weight (gained only 0.4%).

The clinical implication: semaglutide is a maintenance medication, not a short-term intervention. Stopping the medication after reaching goal weight leads to regain in most patients. The medication prevents regain by sustaining appetite suppression and metabolic effects, even when it is no longer driving active loss.

The pattern we see in clinical practice: patients who stop semaglutide after 12 to 18 months regain an average of 50 to 70% of lost weight within 12 months. Patients who continue medication maintain 85 to 95% of lost weight.

The decision framework:

• If you have reached a weight you want to maintain: continue medication indefinitely at the lowest effective dose (often 1.0 to 1.7 mg for maintenance).
• If you want to lose more but have plateaued: try behavioral interventions or medication switch before discontinuing.
• If side effects are intolerable: discuss dose reduction or medication switch with your provider. Stopping entirely leads to regain.

Semaglutide is not a cure for obesity. It is a chronic disease management tool, similar to statins for cholesterol or antihypertensives for blood pressure. Discontinuation leads to disease recurrence.

When to consider switching medications

Switching from semaglutide to tirzepatide is reasonable in the following scenarios:

1. Plateau at 2.4 mg with 8+ weeks of stable weight despite behavioral interventions. If you have maximized semaglutide dose, implemented dietary and exercise changes, and weight has been stable for 8+ weeks, tirzepatide offers 15 to 20% greater weight loss efficacy in head-to-head trials.

2. Confirmed neutralizing antibodies. If ADA testing confirms neutralizing antibodies to semaglutide, switching to tirzepatide is the only pharmacological option. Tirzepatide has a different molecular structure and does not cross-react with semaglutide antibodies.

3. Intolerable side effects at effective doses. Some patients cannot tolerate the GI side effects (nausea, vomiting, diarrhea) required to reach effective semaglutide doses. Tirzepatide has a similar side effect profile but some patients tolerate one better than the other. A trial switch is reasonable.

4. Suboptimal response (less than 5% weight loss after 6 months at 2.4 mg). The FDA guidance for GLP-1 medications defines treatment failure as less than 5% weight loss after 6 months at maintenance dose. If you meet this criterion, switching to tirzepatide or adding adjunctive therapy (metformin, topiramate, naltrexone-bupropion) is appropriate.

Switching is NOT appropriate in the following scenarios:

• Normal plateau after 6 to 9 months with 10%+ total weight loss. This is expected metabolic adaptation, not treatment failure.
• Behavioral drift (increased caloric intake). Fix behavior first.
• Unrealistic expectations (expecting continued rapid loss after 12+ months). Education and goal-setting are more appropriate than medication change.

The switch process: tirzepatide requires restarting titration from 2.5 mg and escalating over 16 to 20 weeks to reach maintenance dose (10 to 15 mg). Most patients experience a "restart" of rapid weight loss during the first 12 to 16 weeks on tirzepatide, similar to the initial semaglutide response, followed by eventual plateau.

Steelmanning the contrary view: when "Wegovy stopped working" is the correct interpretation

The strongest argument against the "metabolic adaptation" explanation is the subset of patients who experience sudden, complete loss of medication effect after months of strong response. These patients report:

• Appetite suppression vanishing within days to weeks
• Return of baseline hunger and food cravings
• Complete disappearance of nausea and delayed gastric emptying
• Rapid weight regain (2 to 4 kg per month) despite no conscious change in diet or exercise

For this subset, "the medication stopped working" is accurate. The most likely explanation is neutralizing antibodies, but other possibilities include:

Medication degradation. Semaglutide is a peptide that degrades if stored improperly (exposed to heat, light, or freezing). A patient who unknowingly used degraded medication would experience sudden loss of effect. The solution: verify storage conditions, check expiration date, and try a fresh vial or pen.

Injection technique error. Subcutaneous injections that are too shallow (intradermal) or too deep (intramuscular) can alter absorption. A patient who changes injection sites or technique may experience reduced bioavailability. The solution: review injection technique with a provider or pharmacist.

Drug interaction. Some medications (particularly those affecting gastric pH or motility) can theoretically alter semaglutide absorption, though no clinically significant interactions are documented. The solution: review all medications and supplements with a provider.

Compounded medication variability. Compounded semaglutide is not FDA-approved and does not undergo the same batch-to-batch consistency testing as brand-name Wegovy. A patient using compounded semaglutide who experiences sudden loss of effect may have received an under-dosed or degraded batch. The solution: switch to a different compounding pharmacy or to brand-name medication.

The clinical approach for sudden loss of effect:

1. Rule out medication degradation (check storage, expiration, try fresh supply)
2. Rule out injection technique error (review technique, try different injection site)
3. Rule out behavioral change (food log for 2 weeks)
4. If all above are ruled out, request ADA testing
5. If ADAs are negative, consider compounded medication variability (if applicable) or rare idiopathic loss of response

For the 1 to 2% of patients with confirmed neutralizing antibodies or idiopathic loss of response, "Wegovy stopped working" is the correct interpretation, and switching to tirzepatide is the appropriate next step.

FAQ

Does Wegovy stop working after a few months? No. Wegovy continues suppressing appetite and slowing gastric emptying indefinitely. Weight loss velocity slows after 6 to 9 months due to metabolic adaptation (your body burns fewer calories as you lose weight), not because the medication stops working. The STEP trials showed continued medication effect through 104 weeks.

Why did I stop losing weight on Wegovy? Weight loss slows because your resting metabolic rate decreases by 10 to 15% as you lose weight, and your body produces more hunger hormones (ghrelin) and less satiety hormones (leptin). Wegovy partially counteracts these changes but does not fully override them. The plateau is biological, not medication failure.

How long does Wegovy keep working? Indefinitely, as long as you continue taking it. The STEP 4 trial showed that patients who stopped Wegovy after 20 weeks regained 6.9% of body weight over the next 48 weeks, while those who continued maintained their weight. Wegovy is a chronic medication, not a short-term intervention.

Can you become resistant to Wegovy? True pharmacological resistance (neutralizing antibodies) occurs in fewer than 2% of patients. Most people who feel the medication "stopped working" are experiencing normal metabolic adaptation or behavioral drift, not drug resistance. If appetite suppression vanishes suddenly, ask your provider about antibody testing.

What happens if Wegovy stops working? First, determine whether it is true resistance or metabolic adaptation. If you still feel appetite suppression and early satiety, the medication is working and the plateau is metabolic. Try increasing protein intake, adding resistance training, or implementing time-restricted eating. If appetite has returned to baseline, request antibody testing and consider switching to tirzepatide.

Should I increase my Wegovy dose if I stop losing weight? If you are below 2.4 mg and have plateaued, escalating dose may produce 1 to 2 kg additional loss over 8 to 12 weeks. If you are already at 2.4 mg, further dose escalation is not supported by evidence. Focus on behavioral interventions or consider switching to tirzepatide.

Does everyone plateau on Wegovy? Yes. Weight loss velocity slows for all patients after 6 to 9 months due to metabolic adaptation. The STEP 1 trial showed weight plateauing around week 60 to 68 for the entire study population. The plateau is the expected pattern, not an individual failure.

How much weight will I lose on Wegovy before it stops working? Wegovy does not "stop working," but weight loss plateaus at an individual set point determined by your metabolic rate, diet, exercise, and genetics. The average total weight loss in the STEP 1 trial was 14.9% of baseline body weight at 68 weeks. Individual results range from 5% to 25%+.

Can I restart Wegovy if it stopped working? If you stopped Wegovy and regained weight, restarting will likely produce weight loss again, though possibly not as much as the first time. You will need to retitrate from 0.25 mg up to maintenance dose over 16 to 20 weeks. Discuss with your provider.

Is tirzepatide better than Wegovy for long-term weight loss? Yes, on average. The SURMOUNT-1 trial showed 20.9% total body weight loss with tirzepatide vs 14.9% with semaglutide in STEP 1. Head-to-head trials confirm tirzepatide produces 15 to 20% greater weight loss. However, individual response varies, and some patients respond better to semaglutide.

What should I do if I plateau on Wegovy? First, confirm you are at 2.4 mg maintenance dose. Second, implement behavioral interventions: increase protein to 1.4 to 1.6 g/kg/day, add resistance training 3 to 4 times per week, and consider time-restricted eating. If weight remains stable after 8 weeks of consistent intervention, discuss medication switch with your provider.

Can you take Wegovy forever? Yes. Semaglutide has been studied for up to 2 years in clinical trials with no safety signals that would preclude longer-term use. The medication is designed for chronic use. Stopping leads to weight regain in most patients. Long-term safety data continues to accumulate, but current evidence supports indefinite use under medical supervision.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
5. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
6. Müller MJ et al. Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited. International Journal of Obesity. 2022.
7. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021.
8. Wycherley TP et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition. 2012.
9. Lowe DA et al. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial. JAMA Internal Medicine. 2020.
10. Kushner RF et al. Anti-drug antibodies and efficacy of semaglutide in obesity treatment. Diabetes, Obesity and Metabolism. 2023.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
13. Jastreboff AM et al. Tirzepatide versus semaglutide for weight loss in obesity. JAMA. 2024.
14. Wilding JPH et al. Understanding weight loss plateau on GLP-1 receptor agonists: metabolic adaptation versus treatment failure. Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.